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Mycobacterium tuberculosisA B S T R A C T
Objective/background: The nature and frequency of mutations in rifampicin (RIF) and isoni-
azid (INH) resistant Mycobacterium tuberculosis isolates vary considerably according to geo-
graphic locations. However, information regarding specific mutational patterns in Ethiopia
remains limited.
Methods: A cross-sectional prospective study was carried out among confirmed pulmonary
tuberculosis cases in Southwest Ethiopia. Mutations associated with RIF and INH resis-
tances were studied using GenoType MTBDRplus line probe assay in 112 M. tuberculosis iso-
lates. Culture (MGIT960) and identification tests were performed at the Mycobacteriology
Research Center of Jimma University, Jimma, Ethiopia.
Results: Mutations conferring resistance to INH, RIF, and multidrug resistance were
detected in 36.6% (41/112), 30.4% (34/112), and 27.7% (31/112) of M. tuberculosis isolates
respectively. Among 34 RIF-resistant isolates, 82.4% (28/34) had rpoB gene mutations at
S531L, 2.9% (1/34) at H526D, and 14.7% (5/34) had mutations only at wild type probes. Of
41 INH-resistant strains, 87.8% (36/41) had mutations in the katG gene at Ser315Thr1 and
9.8% (4/41) had mutations in the inhA gene at C15T. Mutations in inhA promoter region were
strongly associated with INH monoresistance.
Conclusion: A high rate of drug resistancewas commonly observed among failure cases. The
most frequent gene mutations associated with the resistance to INH and RIF were observed
in the codon 315 of the katG gene and codon 531 of the rpoB gene, respectively. Further stud-
ies onmutations in different geographic regions using DNA sequencing techniques arewar-
ranted to improve the kit by including more specific mutation probes in the kit.
 2016 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.316 26 24;
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Multidrug-resistant tuberculosis (MDR-TB) has become a
major public health problem and presents a barrier to TB con-
trol [1]. In Ethiopia, MDR-TB is becoming a challenge because
of poor adherence to treatment and use of inappropriate treat-
ment regimens [2]. Moreover, culture and drug susceptibility
testing (DST) for Mycobacterium tuberculosis are not routinely
performed. Only a few laboratories in Ethiopia are equipped
with facilities to perform DST. In 2010, only 10% of MDR-TB
cases were detected [3]. This indicates that a majority of the
expected MDR-TB cases in Ethiopia remain undiagnosed and
continue to transmit the disease in the community.
The World Health Organization (WHO) has proposed a
wide-scale implementation of rapid molecular methods to
screen patients at risk of MDR-TB. Rapid tests can provide
results within days and thus enable rapid and appropriate
treatment, decrease morbidity and mortality, and interrupt
transmission [4]. Among these, line probe assay (LPA) has
been developed for the rapid detection of M. tuberculosis com-
plex and its resistance to rifampicin (RIF) and isoniazid (INH).
The assay detects mutations in the rpoB gene for RIF resis-
tance, the katG gene for high-level INH resistance, and the
inhA gene for low-level INH resistance from smear-positive
or culture-positive sputum sample [5].
Genetic diversities of drug resistant isolates might be attri-
butable to some host factors besides strain evolution in differ-
ent geographic regions [6]. The principal patient-related factor
that is associated with the occurrence of MDR-TB is poor
adherence to TB treatment [7]. In particular, those patients
that have a previous TB treatment history such as treatment
failures, defaulters, or relapse cases are at greater risk of devel-
opingMDR-TB. A study in Northwest Ethiopia [8] reported that
history of previous TB treatment was significantly associated
with gene mutations conferring resistance to INH and RIF.
RIF and INH are the principal first-line drugs used in combi-
nation for TB treatment [9]. More than 95% of RIF-resistantM.
tuberculosis strains harbor a mutation in the 81-bp region of
rpoB, known as the RIF resistance-determining region [10,11].
INH resistance can occur due to mutations in several genes,
such as katG, inhA, kasA, oxyR, and ahpC. However, 70–80% of
INH resistance is associated with mutations in codon 315 of
the katG gene [12,13]. Studies have shown that >90% of RIF-
resistantM. tuberculosis strains are also resistant to INH, mak-
ing RIF resistance a good surrogatemarker forMDR-TB [5,9,14].
The nature and frequency of mutations in the rpoB gene in
RIF-resistantM. tuberculosis strains and katG and inhA genes in
INH-resistant M. tuberculosis strains vary considerably with
geographical locations or ethnic groups [14]. So far in Ethiopia,
there was very limited information on the frequency of gene
mutations associated with resistance to RIF, INH, and MDR
strains in relation to patients’ TB history (new, relapse, failure,
or return after default). Since mutations that cause RIF and
INH resistance in Ethiopia were not well studied, it is difficult
to choose the most efficient and cost-effective molecular
method to detect such mutations in order to guide therapy.
The primary aim of this study was to determine the magni-
tude andmutation profile of RIF- and INH-resistantM. tubercu-
losis strainswith GenoTypeMTBDRplus in Southwest Ethiopia.Materials and methods
Study design and setting
This cross-sectional study was carried out at the
Mycobacteriology Research Center of Jimma University in
Jimma, Jimma, Ethiopia. Jimma University-Mycobacteriology
Research Center is the only laboratory equipped with culture
and DST in the Southwest part of Ethiopia. It was established
as part of interuniversity collaborative research project
between Jimma University and a consortium of Flemish
Universities from Belgium in November 2010. The laboratory
activities are mainly focused on basic research and training
in the field of mycobacteriology. It is also involved in the
provision of service to patients as part of a national mycobac-
teriology laboratory network and referral center for DST in
Southwest Ethiopia.Study participants
Pulmonary-TB cases referred from health facilities in Jimma
and the surrounding area for DST were enrolled. Individuals
were eligible if they were 15 years or older and provided a spu-
tum specimen that was positive for acid-fast bacilli (AFB) on
smear microscopy and/or TB was confirmed subsequently
by growth of theM. tuberculosis in liquid culture (Mycobacteria
Growth Indicator Tube [MGIT] 960). At the time of patient pre-
sentation, study participants were classified according to the
WHO definitions (new, relapse, treatment failure, or default)
[15]. The study was approved by the Ethical Review Commit-
tee of Jimma University. Written informed consent was
obtained from all participants. All confirmed MDR-TB
patients were referred to Shenin Gibe Hospital (a nearby hos-
pital, 5 km) for MDR-TB treatment.Definitions
New cases: patients that have never been treated for TB or
have taken anti-TB drugs for <1 month.
Previously treated cases: patients that have received
P1 month of anti-TB drugs in the past. They are further clas-
sified by the outcome of their most recent course of treatment
as follows:
1. Relapse patients have previously been treated for TB, were
declared cured or treatment completed at the end of their
most recent course of treatment, and are now diagnosed
with a recurrent episode of TB.
2. Treatment failure patients are those who have previously
been treated for TB and whose treatment failed at the
end of their most recent course of treatment.
3. Defaulter (treatment after loss to follow-up) patients have
previously been treated for TB and were declared lost to
follow-up at the end of their most recent course of
treatment.
4. Monoresistance is resistance to one first-line anti-TB drug
only (RIF or INH).
5. MDR is resistance to both INH and RIF.
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or without resistance to INH.Specimen collection and transport
Morning sputum sample was collected from each of the TB
cases in 50-mL sterile falcon tubes. All specimenswere packed
and transported to Jimma University-Mycobacteriology
Research Center according to the international standards of
WHO recommendation for transport of biological substances
and arrived within 3 days of collection for processing within
7 days of its collection.
Sputum smear microscopy
Smears were prepared on the spot of specimen collection or
acceptance on clean slides. Standard Ziehl–Neelsen staining
procedure was applied [16]. Stained slides were examined
for AFB under a 100 oil immersion objective. AFB results
were reported for the presence or absence of AFB using the
WHO/International Union Against Tuberculosis and Lung Dis-
ease scale, with a positive result corresponding toP1 AFB per
100 high-power fields.
Culture and identification
Mycobacterial culture and identification was done in a Biosaf-
ety Level-2 laboratory following the standard protocols [17]. All
sputum specimens were digested and decontaminated by the
standard N-acetyl-L-cysteine and sodium hydroxide method
with a final sodium hydroxide concentration of 1%. An equal
volume of standard N-acetyl-L-cysteine and sodiumhydroxide
solution was added to the specimen and incubated for 15 min.
After centrifugation, the sedimentwas resuspended in 1 mL of
sterile phosphate buffered saline (pH = 6.8). Finally an aliquot
of 0.5-mL sediment was inoculated into a MGIT 960 tube and
loaded into a BACTEC MGIT 960 instrument. The laboratory
strain,M. tuberculosisH37Rv, (American Type Culture Collection
27294), was used as a positive control.
Differentiation of M. tuberculosis complex from non-TB
mycobacteria (NTM) was done using a SD BIO LINE MPT64
TB Ag test (Standard Diagnostics, Yongin, South Korea). One
hundred microliter of sample sediment taken from processed
smear positive sputum or 100 lL of mycobacterial growth
taken from positive MGIT culture was added into the sample
well. The test result was interpreted within 15 min of sample
addition.
GenoType MTBDRplus (version 2.0) DST
The GenoType MTBDRplus assay was performed according to
the manufacturer’s instruction (Hain Lifescience, Nehren,
Germany). DNA was extracted from decontaminated smear-
positive sample sediment or from MGIT culture positives.
Briefly, smear-positive sputum specimens were decontami-
nated using N-acetyl-L-cysteine-sodium hydroxide [17]. After
resuspension, 500-lL decontaminated sample was trans-
ferred to a 1.5-mL microcentrifuge tube and centrifuged at
10,000g for 15 min. The supernatant was discarded and thepellet was resuspended in 100-lL lysis buffer, incubated for
5 min at 95 C in a hot air oven. Then 100-lL neutralization
buffer was added and centrifuged for 5 min at 10,000g. Finally,
5-lL of the DNA supernatant was used for polymerase chain
reaction while the remainder was stored at 20 C. For
culture-positive cases, 1 mL of liquid culture was transferred
to a microcentrifuge tube and centrifuged for 15 min at
10,000g. The supernatant was discarded and the same proce-
dure as in the case of direct sputum proceeded starting from
the addition of lysis buffer.
A master mixture for amplification consisted of 35-lL pri-
mer nucleotide mixture (provided with kit), 5 lL of 10 poly-
merase chain reaction buffer with 15 mM MgCl2, 2 lL of
25 mM MgCl2, 0.2 lL (1 U) of HotStarTaq DNA polymerase
(Hain Lifescience, Nehren, Germany), 3-lL nuclease free
molecular grade water, and 5 lL of DNA supernatant in a final
volume of 50 lL. The amplification protocol consisted of
15 min of denaturation at 95 C, followed by 10 cycles compris-
ing denaturation at 95 C for 30 s, and 65 C for 2 min. Thiswas
followed by 20 cycles comprising 95 C for 25 s, 50 C for 40 s,
and 70 C for 40 s, and a final extension at 70 C for 8 min.
Hybridization was performed with the automatic machine
(TwinCubator). After hybridization and washing, strips were
removed, fixed on paper, and results were interpreted.
Each strip of Genotype MTBDRplus assay has 27 reaction
zones (bands), including six controls (conjugate, amplifica-
tion, M. tuberculosis complex, rpoB, katG, and inhA controls),
eight rpoB wild-type (WT1–WT8), and four mutant (MUT)
probes (rpoB MUT D516V, rpoB MUT H526Y, rpoB MUT H526D,
and rpoBMUT S531L), one katGWTand two MUT probes (katG
MUT S315T1 and katG MUT S315T2), and two inhA WT and
four MUT probes (inhA MUT1 C15T, inhA MUT2 A16G, inhA
MUT3A T8C, and inhA MUT3B T8A).
An internal quality control program with positive and neg-
ative controls was implemented during the study. An inter-
pretable Genotype MTBDRplus assay was defined as a test
strip with all control markers positive, including results of
the markers for positive control (H37Rv strain), negative con-
trol for DNA extraction, and for mix preparation. If a WT band
was missing or if a MUT band was present, this was taken as
an indication of a resistant strain.
Statistical analysis
Data were double entered and analyzed using SPSS version 16
(SPSS Inc., Chicago, IL, USA). Descriptive data were presented
as frequency (percentage). The rate of mutations in rpoB, katG,
and inhA genes in the categories of patients (new, relapse, fail-
ure, or defaulter) were estimated. Chi-square test was applied
to assess factors associated with drug resistance. A p
value < .05 was taken as statistically significant.
Results
A total of 122 smear- and/or-culture positive cases from Octo-
ber 2013 to September 2014 were included in this study. M.
tuberculosis was isolated in 96.7% (118/122) of patients and
NTM in four patients. Of 118 M. tuberculosis isolates subjected
for LPA test, six had invalid results. Patients with NTM and
invalid LPA results were excluded, leaving 112 TB patients
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were men. The age of the study participants ranged from
15 years to 75 years with a median age of 28.5 (±13.5 standard
deviation) years. Based on their TB-treatment history, 36.6%
(41/112) of patients were classified as new, 28.6% (32/112) fail-
ure, 26.8% (30/112) relapse, and 8% (9/112) defaulter.
Out of 112 M. tuberculosis isolates, 60.7% (68/112) were sus-
ceptible to both RIF and INH, 2.7% (3/112) were RIF monoresis-
tant, and 8.9% (10/112) were INHmonoresistant. Resistance to
RIF and/or INH was noted in 39.3% (44/112) of patients. MDR-
TB (resistance to both RIF and INH) was found in 27.7%
(31/112) of the cases. MDR-TB was most frequently seen
among failure cases (50%), followed by defaulters (33.3%),
and relapse cases (23.3%; Table 1).
Men accounted for the majority, 71% (22/31), of MDR-TB
patients. More than half, 51.6% (16/31), of MDR-TB patients
were found in the age range of 15–25 years. Neither sex nor
age of the patients was significantly associated with MDR-
TB (p > .05). Unlike INH-resistant strains (p = .98), RIF-
resistant strains were most frequently seen in male patients
(p = .043). Mutations conferring resistance to RIF (p = .02),
INH (p = .01), and MDR-TB (p = .004) commonly occurred in
treatment failure cases compared with other treatment cate-
gories (Table 2).Table 2 – Patient characteristics and their association with resist
MTBDRplus line probe assay (n = 112).
Patient characteristics RIF and INH resistance pattern
RIF p
Sex
Male (n = 63) 24 (38) .043
Female (n = 49) 10 (20.4)
Age (y)
15–25 (n = 42) 16 (38)
26–35 (n = 34) 10 (29.4) .24
36–45 (n = 16) 6 (37.5)
46–55 (n = 12) 1 (8.3)
>55 (n = 8) 1 (12.5)
TB Tx history
New (n = 41) 7 (17)
Failure (n = 32) 16 (50) .02
Relapse (n = 30) 8 (26.7)
Default (n = 9) 3 (33.3)
Note: Data are presented as n (%). MDR = multidrug resistance; Tx = treat
Table 1 – Rifampin (RIF) and Isoniazid (INH) resistance pattern i
relapse, and default; n = 112).
Resistance pattern New (n = 41) Failure
Susceptible to RIF & INH 32 (78) 13 (40
Resistance to RIF & INHa 5 (12.2) 16 (50
RIF monoresistance 2 (4.9) 0
INH monoresistance 2 (4.9) 3 (9.4)
Note: Data are presented as n (%).
a Resistance to rifampin and isoniazid is defined as multidrug resistantMutation patterns in RIF- and INH-resistant strains
Frequency of gene mutations associated with resistance to
RIF (rpoB) and INH (katG and inhA) in relation to TB-
treatment history is shown in Table 3. Mutations conferring
resistance to RIF and INH were detected in 30.4% (34/112)
and 36.6% (41/112) of M. tuberculosis isolates respectively.
Among 34 RIF-resistant isolates, 82.4% (28/34) had a mutation
at position S531L and 2.9% (1/34) at position H526D (Table 3).
In five of 34 RIF-resistant isolates, only WT probes (4 rpoB
WT8 and 1 rpoB WT7) were missing with no gain in mutant
probes (Table 4). These later isolates were depicted as
unknown. But in 82.4% (28/34) of RIF-resistant isolates, rpoB
gene mutations detected at WT probes were also detected at
MUT probes (27 rpoB WT8/rpoB MUT3 and 1 rpoB WT7/rpoB
MUT2). The majority, 83.9% (26/31), of MDR-TB strains and
66.6% (2/3) of RIF-monoresistant strains had a mutation in
rpoB (codon 531) gene with an amino acid change of Ser531-
Leu. The difference of rpoB gene mutation in MDR-TB strains
compared with RIF-monoresistant strains was not statisti-
cally significant (p = .06; Table 4).
Resistance to INH is associated with a mutation at two
genes; katG and inhA. Of 41 INH-resistant isolates, 90.2%
(37/41) had a mutation in the katG gene, while 9.8% (4/41) inance to rifampin (RIF) and isoniazid (INH) based on GenoType
INH p MDR p
23 (36.5) .98 22 (34.9) .052
18 (36.7) 9 (18.4)
20 (47.6) 16 (38)
10 (29.4) .20 8 (23.5) .21
7 (43.8) 5 (31.2)
3 (25) 1 (8.3)
1 (12.5) 1 (12.5)
7 (17) 5 (12.2)
19 (59.4) .01 16 (50) .004
10 (33.3) 7 (23.3)
5 (55.6) 3 (33.3)
ment.
n relation to tuberculosis treatment history (new, failure,
(n = 32) Relapse (n = 30) Defaulter (n = 9)
.6) 19 (63.3) 4 (44.4)
) 7 (23.3) 3 (33.3)
1 (3.3) 0
3 (10) 2 (22.2)
tuberculosis.
Table 3 – Frequency of gene mutations associated with resistance to rifampicin (rpoB) and isoniazid (katG or inhA) in relation
to tuberculosis (TB) treatment history.
Gene Band Gene region/mutation TB treatment history
Total (n = 34) New (n = 7) Failure (n = 16) Relapse (n = 8) Default (n = 3)
rpoB
WT1 506–509 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
WT2 510–513 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
WT3 513–517 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
WT4 516–519 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
WT5 518–522 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
WT6 521–525 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
WT7 526–529 2 (5.9) 0 (0) 2 (12.5) 0 (0) 0 (0)
WT8 530–533 31 (91.2) 7 (100) 14 (87.5) 7 (87.5) 3 (100)
MUT1 D516V 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
MUT2A H526Y 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
MUT2B H526D 1 (2.9) 0 (0) 1 (6.3) 0 (0) 0 (0)
MUT3 S531L 28 (82.3) 5 (71.4) 13 (81.3) 8 (100) 2 (66.7)
Gene Band Gene region/mutation Total (n = 41) New (n = 7) Failure (n = 19) Relapse (n = 10) Default (n = 5)
katG
WT 315 31 (75.6) 7 (100) 14 (73.7) 8 (80) 2 (40)
MUT1 S315T1 36 (87.8) 6 (85.7) 17 (89.5) 10 (100) 3 (60)
MUT2 S315T2 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
inhA
WT1 15/16 4 (9.8) 0 (0) 2 (10.5) 0 (0) 2 (40)
WT2 8 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
MUT1 C15T 4 (9.8) 0 (0) 2 (10.5) 0 (0) 2 (40)
MUT2 A16G 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
MUT3A T8C 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
MUT3B T8A 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Note: Data are presented as n (%). MUT = mutant; WT = wild type.
Table 4 – Mutation pattern of rifampicin (RIF; rpoB) and isoniazid (katG and inhA) resistant Mycobacterium tuberculosis strains
by GenoType MTBDRplus assay.
Gene Mutation pattern
(wild type/mutant)
Amino acid change RIF resistant (n = 34) MDR-TB (n = 31) RIF-MR (n = 3) p
rpoB
rpoB WT8/rpoB MUT3 S531L 27 (79.4) 26 (83.9) 1 (33.3) .06a
rpoB WT8/ND Unknown 4 (11.8) 3 (9.7) 1 (33.3)
rpoB WT7/rpoB MUT2B H526D 1 (2.9) 1 (3.2) 0 (0)
rpoB WT7/ND Unknown 1 (2.9) 1 (3.2) 0 (0)
rpoB MUT3 S531L 1 (2.9) 0 (0) 1 (33.3)
Mutation pattern
(wild type/mutant)
Amino acid change INH resistant (n = 41) MDR-TB (n = 31) INH-MR (n = 10) p
katG
KatG WT/katG MUT1 S315T1 30 (73.2) 24 (77.4) 6 (60) .002b
KatG WT/ND Unknown 1 (2.4) 1 (3.2) 0 (0)
katG MUT1 S315T1 6 (14.6) 6 (19.4) 0 (0)
inhA
inhAWT1/inhA MUT1 C15T 4 (9.8) 0 (0) 4 (40)
Note: Data are presented as n (%).
a RIF-monoresistant versus MDR-TB.
b INH-monoresistant versus MDR-TB. INH-MR = isoniazid monoresistant; MUT = mutant; ND = not detected; RIF-MR = rifampicin monoresis-
tant; WT = wild type.
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Ser315Thr1 was documented most frequently and seen in
87.8% (36/41) of INH-resistant isolates. Six katG genemutations detected at MUT probes (katG MUT1) were not pre-
sent in wild probes but all inhA gene mutations detected at
WT probes were also present at MUT probes. Only one had
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There was no combined katG and inhA gene mutations found
among INH-resistant isolates.
All MDR-TB strains and 60% (6/10) of INH-monoresistant
strains had mutations at the KatG gene. However, 40% (4/10)
of INH-monoresistant strains and none of the MDR-TB strains
had a mutation at the inhA gene. This difference of mutations
in MDR-TB strains compared with INH-monoresistant strains
was statistically significant (p = .002; Table 4). Mutations at the
KatG gene were significantly associated with MDR-TB com-
pared with inhA gene mutations.
Discussion
Drug resistance in M. tuberculosis appears to result from the
stepwise acquisition of new mutations in the genes for differ-
ent drug targets [18]. Resistance to drugs is mainly due to
treatment that is inadequate, often because of an irregular
drug supply, inappropriate regimens, or poor compliance
[19,20]. Genetic characterization and identification of muta-
tions that cause resistance will allow the selection of most
efficient molecular methods to detect suchmutations in order
to optimize an effective antibiotic treatment. In the present
study, we determined the frequency of gene mutations asso-
ciated with RIF and INH resistance in M. tuberculosis strains
among pulmonary TB patients.
Similar to other developing countries such as India, Bangla-
desh, and SouthAfrica, there is a high rate ofMDR-TB in Ethio-
pia [2,3]. This is proving to be an emerging threat to TB control
because very few laboratories in Ethiopia are equipped with
DST facilities. The overall MDR-TB rate of 27.7% observed in
this study is higher than 11.8% estimated in the WHO 2011
report [3] and 18% documented in a drug resistance survey
in Ethiopia [21] but lower than 46% reported in Addis Ababa,
Ethiopia by Abate et al. [22]. In our study, the treatment failure
category predicted a high rate of drug resistance, with 59.4% of
patients in this category exhibiting resistance to INH and 50%
resistance to RIF and INH. This is because adding one drug in
the failing regimen could change susceptible strains and lead
to MDR. The ‘‘treatment failure” category could be used to
identify patients who may benefit from alternative regimens
instead of the current standard retreatment regimen.
The genetic basis of antibiotic resistance in M. tuberculosis
isolates has been widely studied [8,23,24]. This is the first
report of mutation patterns associated with drug resistance
in M. tuberculosis isolates from Southwest Ethiopia. Mutations
conferring resistance to RIF and/or INH were detected in
39.3% of M. tuberculosis isolates. Several studies have shown
that >95% of RIF-resistant strains harbor a mutation within
the 81-bp region of the rpoB gene [10,11]. In this study, the
most common mutation among RIF-resistant isolates was at
position Ser531Leu, seen in 82.4% of the cases. Similarly, pre-
vious studies indicated [8,25] this was the most frequently
reported mutation in RIF-resistance isolates in Ethiopia. How-
ever, in five (14.7%) of our RIF-resistant isolates, only a WT
band (found in drug-susceptible strains) was missing, but a
corresponding MUT band (found in drug-resistant strains)was not present. It is likely that this banding pattern is the
result of mutations associated with drug resistance. However,
there is a slight possibility that the pattern represents a silent
mutation, one that does not result in an amino acid change or
may indicate the presence of less common mutations at the
rpoB gene that cannot be detected by the current Version 2
of the GenoType MTBDRplus assay.
In GenoType MTBDRplus assay, INH resistance is detected
by probes of two genes; katG and inhA. Results reported from
many areas of the world and Ethiopia [8,12,13] have shown
that katG mutations vary geographically, but 40–95% of INH
resistance was due to katG gene mutations of which 75–90%
of resistant isolates involved base changes at codon 315 of
the katG gene. In agreement with these results, we found that
>85% of INH-resistant strains from Jimma and surrounding
areas have a mutation at codon 315 of the katG gene. Previous
studies have also shown that 8–43% of INH resistance were
mainly caused by the mutations in the promoter region of
the inhA gene [13,26]. In our study, 10% of INH-resistant
strains were associated with mutations in the promoter
region of the inhA gene (mutation in codon C15T). All inhA
gene mutations were found only in INH-monoresistant
strains. However, mutations at the katG gene were most fre-
quently associated with rpoB gene mutations, making katG
mutation a better predictor of MDR-TB compared with inhA
gene mutations.
It is interesting to note that monoresistance to INH is
relatively common while monoresistance to RIF is rare. In
fact, nearly 90% of RIF-resistant strains are also INH resis-
tant, making RIF resistance a good surrogate marker for
MDR-TB [5,9]. In this study, three RIF-resistant isolates were
not MDR-TB (RIF monoresistance). This finding is slightly
higher than previous studies that reported a very low RIF-
monoresistance rate by phenotypic DST in Ethiopia [22,27].
This could be explained by the presence of some unidenti-
fied mutations in other genomic regions (like kasA, oxyR,
and ahpC) of INH-resistant M. tuberculosis isolates that were
not targeted by the assay (GenoType MTBDRplus) used in
the present study. This emphasizes the importance of col-
lecting more information on the local prevalence of drug
resistance (RIF monoresistance) patterns before implement-
ing molecular assays such as GeneXpert MTB/RIF test.
Conclusions
There was high rate of MDR-TB among previously treated
patients, particularly in the treatment failure category, in
Southwest Ethiopia. The most dominant gene mutations
associated with resistance to INH and RIF were observed in
codon 315 of the katG gene and codon 531 of the rpoB gene
in Ethiopia. Mutations in the inhA promoter region were
strongly associated with INH monoresistance. Since there
are clear geographical differences in the presence and propor-
tion of resistance-related mutations, it is crucial to study
more drug-resistant clinical isolates from different regions
of the country to improve the kit by including more specific
mutation probes.
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